SCHEMBL2303871

SCHEMBL2303871

COSc1ccc(O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.50
CYP3A4 P08684 3/20 0.42
HSD17B10 Q99714 3/20 0.42
CA12 O43570 2/20 0.42
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
CA9 Q16790 2/20 0.42
CA14 Q9ULX7 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALOX15 P16050 2/20 0.42
HIF1A Q16665 2/20 0.42
LMNA P02545 2/20 0.42
TYR P14679 2/20 0.42
HPGD P15428 2/20 0.42
KDM4E B2RXH2 1/20 0.42
NPC1 O15118 1/20 0.42
GMNN O75496 1/20 0.42
ALDH1A1 P00352 1/20 0.42
CA3 P07451 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzenethiol SCHEMBL9678426 0.84 NR1H2 (0.37) NR1H2CYP3A4CA12CA1CA2
SCHEMBL19865715 0.80 NR1H2 (0.46) NR1H2CYP3A4HSD17B10CA12CA1
SCHEMBL10835149 0.80 CYP3A4 (0.59) CYP3A4HSD17B10ALOX15HIF1AESR2
SCHEMBL583468 0.78 NR1H2 (0.55) NR1H2CYP3A4HSD17B10CA12CA1
Methoxymethane SCHEMBL10979307 0.76 NR1H2 (0.78) NR1H2CYP3A4HSD17B10CA12CA1
SCHEMBL15097492 0.76 CYP1A1 (0.45) ALOX15LMNAALDH1A1SLC6A2SLC6A4
SCHEMBL8265860 0.76 ACHE (0.44) HSD17B10CA1CA2CA9MEN1
SCHEMBL7523445 0.75 NR1H2 (0.41) NR1H2CYP3A4HSD17B10CA12CA1
SCHEMBL2303866 0.74
SCHEMBL22631937 0.74 CYP2A6 (0.42) MEN1KMT2AALOX15LMNAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192178-A2 RUFOMYCINS AND DERIVATIVES THEREOF USEFUL AS INHIBITORS OF MULTI-DRUG RESISTANCE ASSOCIATED PROTEIN-1 (MRP-1) ELI LILLY AND COMPANY (US) 2002-04-03 EP claimed
WO-2000078795-A2 RUFOMYCINS AND DERIVATIVES THEREOF USEFUL AS INHIBITORS OF MULTI-DRUG RESISTANCE ASSOCIATED PROTEIN-1 (MRP-1) ELI LILLY AND COMPANY (US) 2000-12-28 WO claimed
US-5805326-A Optical limiter structure and method THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1998-09-08 US claimed
US-11945802-B2 Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same MIYOSHI OIL & FAT CO., LTD. (JP) 2024-04-02 US disclosed
EP-4282922-A2 ADDITIVE FOR IMPARTING ULTRAVIOLET ABSORPTIVITY AND/OR HIGH REFRACTIVE INDEX TO MATRIX, AND RESIN MEMBER USING SAME Miyoshi Oil & Fat Co., Ltd. (JP) 2023-11-29 EP disclosed
WO-2023190836-A1 ADDITIVE FOR RESIN, METHOD FOR PRODUCING SAME, AND METHOD FOR SUPPRESSING COLORATION OF RESIN ミヨシ油脂株式会社 2023-10-05 WO disclosed
EP-3178898-B1 ADDITIVE FOR IMPARTING ULTRAVIOLET ABSORPTIVITY AND/OR HIGH REFRACTIVE INDEX TO MATRIX, AND RESIN MEMBER USING SAME MIYOSHI YUSHI KK (JP) 2023-10-04 EP disclosed
CN-111808320-B Additive for imparting ultraviolet absorbing ability and/or high refractive index to substrate, and resin member using same 三吉油脂株式会社 2023-02-28 CN disclosed
EP-3208285-B2 PRODUCTION METHOD OF AN ETHYLENE AND/OR ALPHA-OLEFIN-BASED IONOMER JAPAN POLYETHYLENE CORP (JP) 2023-01-25 EP disclosed
CN-115584055-A Additive for imparting ultraviolet absorbing ability and/or high refractive index to substrate and resin member using same 三吉油脂株式会社 2023-01-10 CN disclosed
US-11370780-B2 Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same MIYOSHI OIL & FAT CO., LTD. (JP) 2022-06-28 US disclosed
US-6204273-B1 TREATMENT OF ANDROGENIC SENSITIVE DISORDERS SUCH AS ACNE VULGARIS, SEBORRHEA, FEMALE HIRSUTISM, MALE PATTERN BALDNESS, AND BENIGN PROSTATIC HYPERPLASIA. MERCK & CO., INC. 2001-03-20 US disclosed
EP-0724592-B1 16-SUBSTITUTED-4-AZA-ANDROSTANE 5-ALPHA-REDUCTASE ISOZYME 1 INHIBITORS MERCK & CO INC (US) 1999-01-07 EP disclosed
US-5805326-A Optical limiter structure and method THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) 1998-09-08 US disclosed
US-5739137-A 16-substituted-4-aza-3-oxo-androstane as 5-alpha-reductase isozyme 1 inhibitors MERCK & CO., INC. (US) 1998-04-14 US disclosed
US-5719158-A 16-substituted-4-aza-androstane 5-alpha-reductase isozyme 1 inhibitors MERCK & CO., INC. (US) 1998-02-17 US disclosed
EP-0393574-A2 Hexitol derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-10-24 EP disclosed
EP-0285564-A1 Antistatic and electrically conductive polymers and moulding compositions CIBA-GEIGY AG (CH) 1988-10-05 EP disclosed
EP-0099303-B1 BENZOTHIOPYRANOPYRIDINONES AND THEIR SALTS, THEIR PREPARATION AND USE AS MEDICAMENTS, AND COMPOSITIONS CONTAINING THEM ROUSSEL-UCLAF (FR) 1987-08-19 EP disclosed
EP-0154495-A2 Improvements in or relating to thioether macrolide derivatives Omura, Satoshi (JP) 1985-09-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11945802-B2 Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same INTS9, MMS19, F12 NR1H2 2791/4885CYP3A4 3535/4885HSD17B10 2873/4885
US-11370780-B2 Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same MMS19, INTS9, SRRM2 NR1H2 1671/4885CYP3A4 3136/4885HSD17B10 2196/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.